Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
major depressive disorder
Biotech
Cybin psychedelic reduces depression severity after 12 months
Seven patients saw their scores improve on the Montgomery–Åsberg Depression Rating Scale.
Darren Incorvaia
Nov 18, 2024 12:57pm
Alto's midphase depression trial falls flat
Oct 23, 2024 4:47am
Supernus links depression drug to fast responses in ph. 2 trial
Oct 18, 2024 9:17am
Abbott begins neuromodulation trial in drug-resistant depression
Sep 4, 2024 11:02am
J&J's oral add-on aces phase 3 in major depressive disorder
May 29, 2024 11:55am
Neurocrine-Takeda antidepressant hits main mark in phase 2 trial
Apr 23, 2024 10:44am